Next, we measured the MACC1 protein levels in tumour samples and found that the in vivo treatment of SS-b2 significantly downregulated MACC1 and c-Met expression and Akt protein phosphorylation, while it enhanced the phosphorylation of BAD (Figures 2(c) and 2(d)). The gene discussed is AKT1; the disease is neoplasm.